{"id":"W2013246214","doi":"10.1159/000048240","title":"Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial","year":2002,"lang":"en","type":"article","venue":"Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada); University of Toronto; Mount Sinai Hospital","funders":"Eli Lilly and Company","keywords":"Medicine; Gemcitabine; Neutropenia; Nausea; Metastatic breast cancer; Chemotherapy; Internal medicine; Surgery; Phases of clinical research; Performance status; Breast cancer; Cancer; Vomiting; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008058198,0.0001832813,0.0005410481,0.0001452381,0.00007073512,0.000003610777,0.0000641861,0.00007953052,0.01146376],"category_scores_gemma":[0.00001057761,0.0001291817,0.00006004095,0.000264805,0.00008956031,0.00005514291,0.00002087039,0.0001836585,0.00005411983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004056094,"about_ca_system_score_gemma":0.0001525942,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004598269,"about_ca_topic_score_gemma":0.0007332067,"domain_scores_codex":[0.9989187,0.00007564072,0.0002697669,0.000271615,0.0001493327,0.0003150107],"domain_scores_gemma":[0.999438,0.00008924318,0.0001125667,0.00015223,0.00007786184,0.0001301065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4037568,0.08661307,0.04035444,0.00004092777,0.0009189059,0.0005518808,0.001778816,0.00002586921,0.000179963,0.00003983049,0.01660351,0.449136],"study_design_scores_gemma":[0.7277702,0.1425578,0.01395396,0.00003248975,0.0003608025,0.00007054779,0.00001996179,0.0001563446,0.00008493623,0.00003299623,0.1147732,0.0001866822],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852032,0.0006301321,0.0000021025,0.01001174,0.0004167491,0.001425852,0.00006562399,0.00003227711,0.002212323],"genre_scores_gemma":[0.9938087,0.001086522,0.00009137377,0.002100455,0.0003298073,0.0004542364,0.00007173227,0.00002501689,0.002032166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4489493,"threshold_uncertainty_score":0.9894399,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04271448628610791,"score_gpt":0.3772395463558425,"score_spread":0.3345250600697346,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}